Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors

Nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39) inhibitors have potential as novel drugs for the (immuno)therapy of cancer. They increase the extracellular concentration of immunostimulatory ATP and reduce the formation of AMP, which can be further hydrolyzed by ecto-5’-nucleotidase (CD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Schäkel, Laura, Schmies, Constanze C., Idris, Riham M., Luo, Xihuan, Lee, Sang-Yong, Lopez, Vittoria, Mirza, Salahuddin, Vu, The Hung, Pelletier, Julie, Sévigny, Jean, Namasivayam, Vigneshwaran, Müller, Christa E.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7508162/
https://ncbi.nlm.nih.gov/pubmed/33013365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.01294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados